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Abstract 
The effect that Dyskeratosis congenita mutations have on ribosome biogenesis has not 
been fully investigated. Here, I am studying the effect of Dyskeratosis congenita 
mutations using a yeast model system with the goal of identifying impacts on ribosome 
biogenesis. I constructed six haploid yeast strains with a single mutation in the CBF5 
gene each using site-directed mutagenesis and chromosomal integration. First, I screened 
for phenotypic effects on growth on solid and in liquid medium at different temperatures; 
these experiments show normal growth behavior of the mutant strains compared to wild 
type. Second, Cbf5p expression levels were examined in whole-cell extract via western 
blotting analysis, which again did not reveal any difference to wild type. Finally, 
progression through the cell cycle was investigated in synchronized cells. Together, this 
study indicates that individual Dyskeratosis congenita mutations are well tolerated in the 
unicellular eukaryote Saccharomyces cerevisiae. 
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Chapter 1: Introduction 
 
1.1 Dyskeratosis congenita – an inherited bone-marrow failure syndrome 
Dyskeratosis congenita as a term was only suggested in 1930, but the disease was firstly 
described as a syndrome by Professor Zinsser already in 1910; therefore this syndrome is 
also known as Zinsser-Engman-Cole syndrome (Walne and Dokal 2008). The clinical 
diagnosis of Dyskeratosis congenita as a disease was very difficult as it is a progressive, 
multi-systemic disorder with a vast range of severities and a variety of clinical 
presentations such that it can be easily be mistaken for other syndromes. Practitioners at 
that time used to focus on one symptom only which they considered as the most 
prominent clinical feature. That was the case until professor Zinsser diagnosed two 
brothers where the youngest suffered from ear infection and unusual skin pigmentation, 
while the oldest suffered from symptoms including white patches in the mouth as well as 
abnormal nail growth. After thorough examination, it was revealed that both brothers 
shared the same syndrome, and only then Professor Zinsser linked these three symptoms 
(abnormal skin pigmentation, oral leukoplacia and nail dystrophy) together and began 
using them as diagnostic markers for Dyskeratosis congenita (Mason and Bessler 2011). 
Today, in order for a patient to be diagnosed with Dyskeratosis congenita, the patient 
must exhibit, in addition to the three previous classical markers, at least two triads that are 
related to somatic retardation. Since 1910, multiple defects in somatic systems have been 
documented in Dyskeratosis congenita patients that occur either sequentially or together 
including alopecia, dental lesion, dysphagia, dysplasia, hyperthyroid, mental retardation, 
anemia, epiphora, hematological abnormalities etc. In addition, patients are highly 
susceptible to pulmonary retardation and fibrosis, immune deficiency as well as cancer. In 
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the majority of Dyskeratosis congenita cases, the disease eventually progresses to reach a 
point where stem cells fail to regenerate leading to bone barrow failure, and this is the 
main cause of premature death among patients. Following that, the majority of 
Dyskeratosis congenita patients’ deaths are related to pulmonary fibrosis and lastly 
malignancy (Alter, Giri et al. 2009, Bessler, Wilson et al. 2010, Dokal 2011, Angrisani, 
Angrisani et al. 2014). 
Originally, Dyskeratosis congenita was conceived to be an X-linked disorder as all the 
reported cases were male (Vulliamy, Beswick et al. 2008). However, in 1963 Sarrow and 
Hitch reported the first female patient who had multiple Dyskeratosis congenita 
symptoms including the classical triads at age of 31 and had carcinoma in the cervix 
before her death. As no one in her family exhibited any clinical features of Dyskeratosis 
congenita, practitioners diagnosed her with autosomal recessive Dyskeratosis congenita 
(Sorrow and Hitch 1963). In 1971, a Dyskeratosis congenita case with autosomal 
dominant inheritance was reported after discovering another female patient with 
Dyskeratosis congenita clinical features whose mother was asymptomatic, while her 
uncle as well as her father, sister and grandmother suffered from Dyskeratosis congenita 
symptoms, too. In conclusion, Dyskeratosis congenita can be X-linked, autosomal 
recessive or autosomal dominant (Ruggero, Silvia, Piazza et al. 2003, Vulliamy, Beswick 
et al. 2008). 
Up to this date, eleven genes (DCK1, TERC, TERT, NOP10, NHP2, TINF2, ACD, 
TCAB1 (WRD79), CTC1 and RTEL1) have been confirmed by genetic screening to 
contribute to Dyskeratosis congenita. All these genes are encoding for proteins that are 
involved in chromosome maintenance (Islam, Rafiq et al. 2013, Walne, Collopy et al. 
2016). More recently, a research group discovered other genes (USB1, LIG4 and 
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GRHL2) that are homozygous variants of the Dyskeratosis congenita syndrome, and 
patients exhibit the classical Dyskeratosis congenita symptoms (Walne, Collopy et al. 
2016). 
Bone marrow failure is considered one of the classical Dyskeratosis congenita markers, 
and many Dyskeratosis congenita patients have stem cells with short telomeres. In 
eukaryotes, chromosome ends contain a DNA/protein structure known as telomere. In 
most tissues, telomeres get shorter directly right after the first year of life and gradually 
get reduced in length throughout the lifespan (Bessler, Wilson et al. 2010). This reduction 
is a cellular checkpoint for tissues to ensure that cells will not go through uncontrolled 
genetic instability during aging. However, in rapidly dividing tissues such as the bone 
marrow, telomere length reduction could be rather massive and therefore lethal (Marrone, 
Walne et al. 2005). Therefore, in these tissues, telomeres retrieve their length by 
activation of an enzyme known as telomerase. Eventually, rapidly dividing tissues will 
also have short telomeres despite telomerase function which simply is a result of aging. In 
general, telomere length has a direct correlation with the aging process; and therefore, a 
person at a certain age will typically have the same range of telomere length as the aged-
matched control. Therefore, in somatic cells for instance, telomere length decreases 
gradually until cells undergo senescence or apoptosis (Shay and Wright 2004). However, 
this process is much faster among Dyskeratosis congenita patients which explains why 
Dyskeratosis congenita patients have abnormally short telomeres in the stem cells (Shay 
and Wright 2004)  
 
The discovery of telomerase has granted Elizabeth Blackburn, Jack Szostak, and Carol 
Greider a Nobel Prize in 2009 (Corey 2009). Telomerase is a ribonucleoprotein, which 
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contains a telomerase RNA component (TERC) and proteins including telomerase reverse 
transcriptase (TERT, present in all organisms) and other organism-specific proteins such 
as H/ACA proteins (Cbf5, Nop10, Gar1, Nhp2) in mammals (Calado and Young 2008, 
Egan and Collins 2012). The RNA component contains a template region that is used by 
TERT to add a repetitive sequence to the telomeres. This enzymatic activity is crucial to 
maintain chromosome integrity after many rounds of cell division throughout the lifespan 
of an organism (Jaskelioff, Muller et al. 2011, Ale-Agha, Dyballa-Rukes et al. 2014).  
 
 
Figure 1: An illustration of complexes that are implicated in telomere maintenance. These 
consist of the telomerase complex on the right and the shelterin complex on the left. The 
protein complex of H/ACA proteins dyskerin (Cbf5), Nop10, Nhp2 and Gar1 bound to 
TERC is depicted on the right.  
 
In general, the majority of Dyskeratosis congenita patients have either very short or 
relatively short telomeres; therefore, Dyskeratosis congenita is generally believed to be a 
telomere-linked disorder (Vulliamy, Beswick et al. 2008). 
 
1.1.1 X-linked Dyskeratosis congenita 
Most Dyskeratosis congenita cases belong to the X-linked version of the disease 
(McGrath 1999). In 1986, the Connor lab was able to narrow down the location of the 
mutated gene that causes X-linked Dyskeratosis congenita to the locus Xq28. In 1998, 
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Heiss and coworkers identified the gene and called it Dyskeratosis Congenita 1 (DKC1) 
and the corresponding protein dyskerin (Heiss, Knight et al. 1998). Most X-linked 
Dyskeratosis congenita patients are found to have missense mutation in DKC1. So far, 
there are about 50 different missense mutations documented in DKC1, in addition to one 
deletion and one mutation in the promoter region (Connor, Gatherer et al. 1986). Until 
now, researchers have not linked precisely any of the DKC1 mutation to the short 
telomere phenotype (Mason and Bessler 2011). The most severe form of Dyskeratosis 
congenita is X-linked and is known as Hoyeraal-Hreidarsson syndrome. The majority of 
Hoyeraal-Hreidarsson patients are male, but a female case was also reported which results 
from a mutation at the TERC gene. Hoyeraal-Hreidarsson patients exhibit aplastic anemia 
during childhood, as well as growth defects, microcephaly and development defects, and 
almost all of them die during childhood (Vulliamy, Beswick et al. 2008).  
 
1.1.2 Autosomal recessive Dyskeratosis congenita 
The majority of the mutated genes discovered in patients affected by autosomal recessive 
Dyskeratosis congenita are implicated in telomere maintenance; specifically, the 
identified genes are telomerase reverse transcriptase (TERT), NOP10, NHP2, TCAB1 
(WRAP53), and CTC1 (Cunningham, Moreno et al. 2014, Walne, Collopy et al. 2016).  
Families with TERT mutations suffer from either mild or severe forms of aplastic anemia. 
The latter symptom indicates the presence of abnormal telomere length in hematopoietic 
stem cells. Many studies were performed on three generations with this mutated gene 
revealing that the first generation only exhibited mild anemia and somewhat shortened 
telomeres, but not pathogenically enough to express the disease. Other studies on five 
children with TERT mutations show normal blood count as well as normal telomere 
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length. However, during their life, their telomeres were getting shorter at a higher rate 
than in a healthy control (Mason and Bessler 2011) (Dokal 2011, Gu, Fan et al. 2011). 
Nop10 is a very small protein that contributes to telomerase stability and hence telomere 
maintenance. It was found to be mutated among families with consanguineous marriage 
(Vulliamy, Beswick et al. 2008). Both heterozygous and homozygous patients suffer from 
the classical Dyskeratosis congenita symptoms and also display very short telomeres as 
well as low TERC levels, but the disease was much more severe for homozygous 
individuals (Mason and Bessler 2011). Nhp2, similarly to Nop10, was found mutated in 
patients from consanguineous marriages. It is also a small protein that is part of the 
H/ACA sRNP, which is involved in telomere integrity. Individuals showed short 
telomeres as well as low TERC levels (Vulliamy, Beswick et al. 2008, Dokal 2011).  
 
1.1.3 Autosomal dominant Dyskeratosis congenita 
This class involves the telomerase RNA component (TERC), TINF1 and RTEL1. Human 
TERC is a large RNA with three conserved domains, firstly, the pseudoknot which 
contains the template region with the repetitive sequence, second, the CR4-CR5 domain 
to which TERT binds, and lastly, toward the 3’ end the scaRNA domain where a set of 
four proteins (dyskerin, Nop10, Gar1, Nhp2) bind and protect it from degradation (Calado 
and Young 2008, Armanios 2009). 
Many studies show that families with TERC mutations start to have short telomeres only 
at the end of the fourth or the fifth decade of their life, and they are recorded to be 
asymptomatic with mild anemia. Moreover, it is assumed that their children with more 
severe symptoms have inherited the mutated gene as well as the already shortened 
telomeres from their parents. Therefore, Dyskeratosis patients with TERC mutations (as 
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well as some patients with TERT mutations) may die because of haploinsufficiency of 
telomerase (Kirwan and Dokal 2009).  
 
1.2 Pseudouridines 
RNAs are heavily modified, and so far over 100 types of chemical modifications have 
been identified (Kiss 2001). Pseudouridine is the most abundant site-specific nucleotide 
modification that is enzymatically and post-transcriptionally introduced into many RNAs 
(Figure 2) (Roovers, Hale et al. 2006). Although both pseudouridine and uridine share an 
identical molecular mass and the same UV spectrum, pseudouridine is able to contribute 
to RNA stability through an additional hydrogen bond to the remaining RNA nucleotides 
(Spenkuch, Motorin et al. 2014). In fact, the interaction between pseudouridine and 
adenine is more stable than the one between U-A within a helix or at the end of RNA 
helices (Hudson, Bloomingdale et al. 2013).  
 
 
 
Figure 2: Structural differences between uridine and pseudouridine. Uridine is the 
substrate for pseudouridine synthases, which they isomerize to pseudouridine.  
 
The number of pseudouridines in bacteria is limited, and knocking out any of the 
pseudouridine synthase genes has no lethal effect on bacteria. However, the number of 
pseudouridines surges in existence in eukaryotes to reach 100 in human rRNA. So far, 
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thirteen pseudouridine synthases have been identified in humans (Antonicka, Choquet et 
al. 2016, Rintala-Dempsey and Kothe 2017).  
Scientists are not yet able to fully elucidate the structural or functional role of 
pseudouridine within the target RNA. However, pseudouridines are clustered in locations 
that are known to have a vital function within the RNA such as the peptidyltransferase 
region in rRNA (Dunin-Horkawicz, Czerwoniec et al. 2006). It has been suggested that 
pseudouridine increases the overall stability of rRNA structure by providing an extra H 
bond that coordinates a water molecule bridging to the RNA phosphate backbone (Arnez 
and Steitz 1994). This notion was strengthened by the finding that the tRNA structure is 
rigidified by the presence of pseudouridines (Yarian, Basti et al. 1999). Specifically, 
pseudouridines at positions 38, 39 and 55 are found to stabilize tRNA structure (Arnez 
and Steitz 1994). Moreover, in particular pseudouridines in the anticodon domain of 
tRNA are enhancing anticodon–codon interactions which indicates that pseudouridines 
are increasing the accuracy of the translation when compared to the unmodified tRNA 
(Harrington, Nazarenko et al. 1993, Davis, Veltri et al. 1998).  
Pseudouridines are likely integrated to stay; therefore, there are so far no  enzymes known 
in mammals that can reverse pseudouridylation. Pseudouridines leave the organism 
through urine as a nucleoside. An enzyme has been identified that can dephosphorylate 
pseudouridines in humans. This enzyme known as pseudouridine-5’-phosphatase might 
be important to prevent random incorporation of pseudouridines in RNAs during 
transcription (Goldberg and Rabinowitz 1961, Preumont, Rzem et al. 2010, Spenkuch, 
Motorin et al. 2014).  
Detection of pseudouridine sites in RNAs is a challenging task. Often, site-specific 
pseudouridylation in rRNA was predicted based on sequence complementarity to a guide 
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RNA. Detection of site-specific pseudouridylation includes extraction of the total RNAs 
followed by isolating rRNA as 80% of total RNAs is rRNA. Then the RNA mixture is 
treated with N-cyclohexyl-Nʹ-(2-morpholinoethyl)-carbodiimide metho-p-
toluenesulfonate (CMC) and subsequently with strong alkaline treatment to remove any 
unspecific association of CMC with uridines and guanines. The next step is a reverse 
transcriptase assay that results in a premature stop in the presence of CMC-labelled 
pseudouridine (Bakin and Ofengand 1993). The disadvantage of this procedure is that in 
order to reach a detectable threshold, the RNA species should be highly expressed, which 
is not the case for the majority of the RNAs species. Moreover, many RNAs get degraded 
quickly during the CMC and the alkaline treatments. Initially, this was the only detection 
method for pseudouridines at a specific site in a specific RNA. Nowadays, there is global 
pseudouridine detection available by treating all cellular RNAs with CMC which is then 
followed by next-generation RNA sequencing. With this new detection method, many 
additional pseudouridine sites have been found in a vast range of noncoding RNAs as 
well as mRNAs. For example, in addition to rRNA and cytosolic tRNA, many 
pseudouridines sites are found in mitochondrial tRNA, small nuclear RNAs, H/ACA 
sRNA, C/D sRNA, telomerase RNA, 7SK snRNA and many other RNA species (Alfonzo 
2014, Carlile, Rojas-Duran et al. 2014, Lovejoy, Riordan et al. 2014, Schwartz, Bernstein 
et al. 2014).  
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1.2.1 Pseudouridine synthases 
Pseudouridine synthases can be subcategorized into two groups: 1) standalone 
pseudouridine synthases (called the PUS family in eukaryotes) and 2) RNA-guided 
pseudouridine synthases (H/ACA sRNP). Standalone pseudouridine synthases are 
enzymes that have been found in all domains of life. All standalone pseudouridine 
synthase have one or a few known uridine target sites. Standalone pseudouridine 
synthases are proteins that are conducting pseudouridine formation on target uridines by 
sequence recognition or/and structural recognition of the substrate RNA. They are 
targeting mainly tRNA, mitochondrial rRNA and some mRNAs (Rintala-Dempsey and 
Kothe 2017). The second type of pseudouridine synthases (H/ACA sRNP) requires 
complex formation of RNA and protein prior to targeting the substrate uridines that are 
mostly found in rRNAs and small nuclear RNAs, but also some mRNAs.  
All pseudouridine synthases share a very similar catalytic domain that possesses a 
catalytic aspartate residue. In general, the activity of these enzymes does not require any 
energetic investment such as ATP; pseudouridine synthases simply break the glycosidic 
bond between the N1 and C1’ atoms, then the bound is formed again between two C5-C1’ 
atoms. Recently it has been proven that the catalytic aspartate deprotonates  C2’ in the 
ribose ring that leads to breakage of the glycosidic bound and formation of a glycal 
intermediate (Veerareddygari, Singh et al. 2016). Then the uracil ring is either flipped or 
rotated and forms a new carbon-carbon glycosidic bound.  
A human disorder has been identified that arises as a result of mutations in the PUS1 
gene. Pseudouridine target sites in tRNA species (mitochondrial and cytoplasmic tRNAs) 
of this enzyme were not implemented despite the normal cellular localization of PUS1 
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(Bykhovskaya, Casas et al. 2004, Fernandez-Vizarra, Berardinelli et al. 2007) (Patton, 
Bykhovskaya et al. 2005). 
 
1.2.2 H/ACA small Ribonucleoproteins (sRNPs) 
RNA-guided pseudouridine synthases have been identified in archaea and eukaryotes. 
RNAs that guide pseudouridylation belong to the H/ACA class of noncoding RNAs. 
Upon transcription, these H/ACA guide RNAs are transported inside the cell either to the 
nucleolus or the Cajal body. Regardless of their final destination, all H/ACA RNAs bind 
to the same set of proteins and guide formation of pseudouridines in a vast range of RNA 
species. All H/ACA RNAs share one consensus secondary structure which is the 5’-
hairpin-hinge-hairpin-tail-3’ structure. In general, H/ACA sRNAs are 100-150 
nucleotides (nt) in length, but there are a few H/ACA RNAs that reach around 250 nt and 
more (snR30). The length of each hairpin ranges from 60 to 75 nt. Both the hinge and the 
tail regions are stretches of single-stranded sequences. The hinge region contains a 
conserved motif (AnAnnA) called H box that follows the first hairpin. The tail has also a 
conserved sequence (Lermontova, Schubert et al. 2007) called an ACA box that follows 
the 3’ hairpin. The two boxes are serving as a signal for the protein complex to bind as 
well as for subcellular localization (Ueda, Calado et al. 2014). Each hairpin contains two 
stems, the proximal P1 stem and distal P2 stem, that are separated by a large internal loop 
that has unpaired sequences; this internal loop is known as the pseudouridylation pocket. 
Each pseudouridylation pocket has a potential antisense target sequence in noncoding 
RNAs, mainly cytoplasmic rRNA and snRNAs, but also mRNAs (McMahon, Contreras 
et al. 2015, Li, Ma et al. 2016). 
Substrate RNA can be paired to the sequence in the pseudouridylation pocket of an 
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H/ACA guide RNA in a way that the target U and the adjacent nucleotide are always 
unpaired; meanwhile about 3-10 nucleotides that are flanking the target U are paired to 
sequences in the pseudouridylation pocket. It has been proposed that this precise 
arrangement is needed for the isomerization of uridine to pseudouridine (McMahon, 
Contreras et al. 2015).  
 
Figure 3: The consensus secondary structure of H/ACA guide RNA. It consists of two 
hairpins separated by the H box while the second hairpin is followed by the ACA box. 
Each stem has two pockets that base-pair to the substrate RNA shown in pink. The 
position of the modified U is shown in red as a psi symbol representing pseudouridine.  
 
Unlike standalone pseudouridine synthases which have one to a few target sites in 
specific RNAs, H/ACA sRNPs target many uridines in many RNAs species. H/ACA 
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sRNPs are composed of one guide H/ACA RNA and four proteins, Cbf5 in yeast (Dkc1 
in human), Nop10, Nhp2 and Gar1 (Figure 4). H/ACA sRNPs are conserved across 
archaea and eukaryotes, but are not found in bacteria. Notably, more than 10% of the 
human genome can be transcribed into one subtype of H/ACA sRNAs known as AluACA 
RNAs which all bind to the same set of proteins(Ketele, Kiss et al. 2016). The remaining 
types of H/ACA RNAs also bind to the same four proteins. H/ACA sRNPs perform many 
vital functions that will be described latter in this thesis.  
 
Figure 4: Crystal structure of an H/ACA sRNP obtained from Pyrococcus furiosus (PDB 
ID: 3HAY). The protein complex consists of L7Ae (Nhp2 homolog) in sandy color, 
bound to Nop10 in light green, Cbf5 in turquoise and Gar1 in pink. The guide RNA 
bound to L7Ae-Nop1-Cbf5 is shown in orange.  
Cbf5 was originally thought to be a centromere binding protein (centromere binding 
factor 5) giving Cbf5 its name (Jiang, Middleton et al. 1993). This protein is essential in 
yeast and eukaryotes as it cannot be deleted. It is the only pseudouridine synthase that 
directs pseudouridylation in yeast rRNA, as substitution of aspartate 95 in yeast Cbf5 
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with alanine resulted in total absence of pseudouridines in rRNA (Zebarjadian, King et al. 
1999). Based on sequence similarities, Cbf5 belongs to the pseudouridine synthase family 
known as the TruB family. Both enzymes have a similar catalytic domain as well as a 
conserved RNA-binding domain known as pseudouridine synthase and archaeosine 
transglycosylase (PUA) domain (Zucchini, Strippoli et al. 2003). Most knowledge of the 
H/ACA sRNP structure stems from studies of the archaeal H/ACA sRNP complex 
(Gupta, Gurha et al. 2007, Xue, Liang et al. 2007). Reconstituting the yeast H/ACA sRNP 
complex is rather difficult, but in 2011, the crystal structure of the yeast trimeric protein 
complex Cbf5-Nop10-Gar1 was reported (Li, Duan, Li, Yang et al. 2011).  
Saccharomyces cerevisiae Cbf5 contains a catalytic domain compromised of residues 39-
292 which are divided into two subdomains D1 and D2. Both subdomains are joined by a 
structure known as the catalytic cleft. The PUA domain is highly positively charged 
which explains its affinity for RNA. It consists of residues in the N terminus (1-32) and 
the C terminus (266 -351) (Li and Ye 2006). The remaining sequence (352-483) is an 
unstructured tail that contains 10 tandem KKE/D repeats. The PUA domain recognizes 
the Box H and Box ACA in the H/ACA RNAs (Rashid, Liang et al. 2006, Li, Duan, Li, 
Yang et al. 2011). The PUA domain is one of the most ancient RNA recognition domains, 
and it consists of about 64-96 residues forming both and  secondary structures. It is 
found in more than 600 catalytic enzymes from different families in all domains of life 
including archaea and eukaryotes. Many of these enzymes and proteins are known to be 
associated with tRNA, proline synthesis, translation initiation, rRNA modifications and 
ribosome biogenesis (Cerrudo, Ghiringhelli et al. 2014). In most cases, the PUA domain 
is located in the C terminus of the enzyme (Cerrudo, Ghiringhelli et al. 2014). To this 
date, there is no eukaryotic crystal structure of the complete H/ACA sRNP, but in the 
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crystal structure obtained from P. furiosus H/ACA sRNP, the PUA domain interacts with 
the double-stranded guide RNA P1 stem and recognizes the ACA (and the AnAnnA) 
sequence (Pérez‐Arellano, Gallego et al. 2007). The PUA domain in Cbf5 is not part of 
the catalytic domain, but it helps in positioning the target uridines in the active site (Li 
and Ye 2006). In yeast, the PUA domain is much larger than in archaeal Cbf5.  
Nop10 is highly unstructured and contains few hydrophilic amino acids that contribute to 
its tertiary structure stability. It has an elongated structure where the C terminus contains 
an helix and is connected to the N terminus ribbon domain via a linker. Nop10 binds to 
Cbf5 at the D1 subdomain, but also touches the D2 surface as well (Li, Duan, Li, Yan et 
al. 2011).  
Nhp2 is the only protein in the complex that cannot associate directly with Cbf5, rather, it 
is believed to attach to Nop10 as its archaeal L7Ae homolog. Two cases of Dyskeratosis 
Congenita have been linked to Nhp2 mutations that impair its binding to Nop10 (Trahan, 
Martel et al. 2010). Unlike L7Ae, the archaeal homolog of yeast Nhp2, the latter does not 
recognize k-turn motifs in the guide RNA. However, it has been found that yeast Nhp2 
can bind different RNAs non-specifically in vitro (Henras, Dez et al. 2001). The ternary 
complex of Nhp2-Nop10-Cbf5 is recruited to the H/ACA sRNA which aids Nhp2 to 
interact with the guide RNA (Koo, Park et al. 2011).  
Yeast Gar1 is named after the two glycine/arginine rich stretches that are flanking a core 
domain of residues 32-124. Interestingly, Gar1 was the first protein to be purified and 
identified in the H/ACA sRNP complex (Ganot, Caizergues-Ferrer et al. 1997), and yet it 
is the last protein to be assembled to the H/ACA sRNP complex as the Gar1 binding site 
on Cbf5 is initially pre-occupied by the assembly factor Naf1. Gar1’s functional 
16 
 
contribution to the H/ACA sRNPs is to facilitate substrate turnover by interacting with 
the thumb loop in Cbf5 (Wang, Yang et al. 2015).   
 
1.3 H/ACA RNA expression 
The maturation process of H/ACA sRNPs is highly coordinated. In yeast, most snoRNAs 
are transcribed from independent genes; however, a small fraction of snoRNAs is 
encoded by introns in protein-coding genes. As known so far, the majority of H/ACA 
sRNAs in humans are transcribed as introns of a mRNA, therefore their transcription is 
regulated together with the protein-coding gene and they lack independent expression 
regulation. Most human introns are rapidly degraded upon release from pre-mRNA; 
therefore, the most important step in H/ACA sRNP biogenesis is facilitating the initial 
binding of H/ACA sRNAs to the RNP complex thus protecting the nascent H/ACA 
sRNAs from degradation (Bousquet-Antonelli, Henry et al. 1997, Dez, Henras et al. 2001, 
Darzacq, Kittur et al. 2006, Hoareau-Aveilla, Bonoli et al. 2006). The H/ACA sRNA is 
released from introns of pre-mRNAs by exonucleases (Kiss and Filipowicz 1995). All 
H/ACA sRNAs that have been identified to this date are transcribed within pre-mRNA by 
RNA-Pol II. Processing of H/ACA sRNA is usually independent from its location relative 
to the splicing site in the pre-mRNA. In addition, H/ACA proteins can be recruited to the 
H/ACA sRNA even before it is processed from the host nascent mRNA during 
transcription or shortly after. Processing of some H/ACA sRNAs such as U64 is governed 
by the RNA polymerase II machinery (Pol II) as H/ACA RNA cannot be accurately 
processed when transcribed by Pol I or Pol III rather than Pol II. (Richard, Kiss et al. 
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2006).   
Interestingly, many snoRNAs as well as scaRNAs are transcribed as part of a host mRNA 
for proteins that are implicated in ribosome biogenesis (Lestrade and Weber 2006). This 
raises the possibility that H/ACA sRNPs levels can be used as a biological marker to 
reflect an increase of cellular activity such as growth (McMahon, Contreras et al. 2015). 
Many protein levels are increased in response to growth including ribosomal proteins and 
proteins involved in ribosome biogenesis. A few studies show that indeed H/ACA sRNPs 
levels are reflecting an increased cellular demand on protein production. For example, it 
was shown that Dkc1 transcript levels are up-regulated in response to the oncogene c-
Myc (Alawi and Lee 2007). This oncogene is one of the human proteins that is highly 
altered in cancer. C-Myc coordinates the activation of multiple genes that are implicated 
in cellular proliferation including genes for ribosome biogenesis as well as telomerase 
activation (Felsher, Yetil et al. 2010).   
Until now, it is not fully known which factors regulate H/ACA sRNA transcription, and 
whether the regulation itself is different between the H/ACA sRNAs that guide 
pseudouridylation and the ones with other cellular functions. It has been shown that the 
expression levels of distinct sets of H/ACA sRNAs are tissue-specific (Cavaille, Buiting 
et al. 2000, Castle, Armour et al. 2010, Bellodi, McMahon et al. 2013). Furthermore, the 
expression levels of a particular subset of H/ACA sRNAs are deregulated in cancer 
(Bellodi, McMahon et al. 2013).  
 
1.3.1 Assembly and localization of H/ACA sRNPs 
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Assembly of H/ACA snoRNAs and the H/ACA proteins requires two essential 
chaperones, Shq1 and the nuclear assembly factor 1 (Naf1) (Grozdanov, Roy et al. 2009). 
So far, Naf1 and Shq1 are exclusive proteins to eukaryotes, which indicates potential 
functional specificity (Fatica, Dlakic et al. 2002). In yeast for example, a significant loss 
of H/ACA snoRNAs was detected upon depletion of Shq1 and Naf1. It has been found 
that Naf1 stabilizes newly transcribed H/ACA snoRNA, and its recruitment to the newly 
transcribed RNAs is Dkc1 dependent; interestingly, the Dkc1 level was also dependent on 
Naf1 (Darzacq, Kittur et al. 2006). One potential explanation is based on a study using 
chromatin coimmunoprecipitation to show that a complex of Naf1-Cbf5 is recruited to the 
H/ACA snoRNA genes (Ballarino, Morlando et al. 2005). In fact, an early association of 
H/ACA snoRNAs to the trimeric complex of Cbf5-Nop10-Nhp2 (but not Gar1) was 
found at the site of H/ACA sRNAs transcription. It was suggested that Naf1 is involved in 
this early steps of H/ACA snoRNP biogenesis, but upon maturation of the complex, it 
gets replaced by Gar1 (Darzacq, Kittur et al. 2006). Interestingly, Naf1 and Shq1 were 
never detected binding simultaneously to Cbf5 (Grozdanov, Roy et al. 2009). Unlike 
Naf1, Shq1 is not found at the final destinations (nucleolar and the Cajal body) of the 
mature H/ACA sRNP complex. Moreover, it was not found near the newly transcribed 
H/ACA sRNAs genes. In fact, Shq1 binds in vivo only to Cbf5 alone and is not 
associating with any of the H/ACA sRNPs or Naf1 (Grozdanov, Roy et al. 2009). 
Consequently, Shq1 is involved in much earlier steps than Naf1 in H/ACA sRNPs 
biogenesis.  
 
1.3.2 H/ACA sRNAs 
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The class of H/ACA small RNAs was identified almost 50 years ago, but so far the 
functional role of this particular type of RNA is not completely understood. Deregulation 
of H/ACA sRNAs is implicated in diseases including leukemia (Valleron, Laprevotte et 
al. 2012). The H/ACA sRNA class can be divided into two main subgroups according to 
their cellular location: 1) small nucleolar RNA (H/ACA snoRNAs) and 2) small Cajal 
body specific RNA (H/ACA scaRNAs).  
 
1.3.3 H/ACA snoRNAs  
As was described before, these guide RNAs have a consensus secondary structure of two 
hairpins and contain characteristic sequence elements with the H box and the ACA box. 
The majority of H/ACA snoRNAs guide pseudouridylation of many uridines in the 
nascent pre-rRNAs. However, some H/ACA snoRNAs have no known target substrate 
and therefore they have been further classified as orphan H/ACA snoRNAs (Vitali, Royo 
et al. 2003, Fatica and Bozzoni 2014). Many studies show that H/ACA snoRNAs can 
execute functions other than guiding pseudouridylation. In this context, many H/ACA 
sRNAs exhibit tissue specificity indicating that they could conduct variety of cellular 
functions. Interestingly, in some human diseases, H/ACA sRNAs level are distorted. 
Moreover, a subset of H/ACA sno/caRNAs are altered in human diseases, but it is not 
known how and why H/ACA sRNA expression is regulated. Nevertheless, H/ACA 
sRNAs have been used as biological markers for certain cancers such as leukemia 
(Ronchetti, Mosca et al. 2013, Mannoor, Shen et al. 2014). The majority of snoRNAs, 
that are deregulated in cancers, do not display genetic alterations in their genes. However, 
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a group of snoRNAs has been reported with either deletions or nucleotide substitutions 
which are implicated in human disorders, predominantly cancer (Skreka, Zywicki et al. 
2012, Valleron, Laprevotte et al. 2012, Valleron, Ysebaert et al. 2012). Some of the 
cellular functions that have been designated to H/ACA sRNAs will be discussed below 
including hematopoietic stem cell differentiations, stem cell biogenesis, chromatin 
biology and other cellular processes such as cholesterol metabolism.   
 
1.3.4 Hematopoietic stem cell differentiations  
The levels of a specific type of H/ACA sno/scaRNAs are exclusively altered in 
hematopoiesis-related pathologies (Ronchetti, Mosca et al. 2013) including acute 
myeloblastic leukemia (Kocak, Ballew et al. 2014) (Valleron, Laprevotte et al. 2012), 
multiple myeloma (Ronchetti, Todoerti et al. 2012) and peripheral T-cell lymphoma 
(PTCL) (Valleron, Ysebaert et al. 2012). These H/ACA sno/caRNAs are sometimes up-
regulated, but in most of the cases they are down-regulated. Interestingly, there are some 
cases where the down regulation of these H/ACA sno/scaRNAs is independent from the 
host gene level (Ronchetti, Todoerti et al. 2012). In this context, it is not fully known yet 
if there is a post-transcriptional regulation that is dynamically involved in H/ACA sno/sca 
RNA biogenesis in these cells. Nevertheless, the main function of most of these affected 
H/ACA sno/scaRNAs is guiding pseudouridine formation in rRNAs, and there are some 
that are involved in spliceosome RNAs modification.  
One study examined hematopoietic stem cell differentiation in CD34+ cells with a 
mutation in the promoter region of the Dkc1 gene. Firstly, the authors tested H/ACA 
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snoRNA and scaRNA levels as well as TERC abundance and telomere length. While both 
TERC levels and telomere length were normal, there was a heterogenic reduction in some 
H/ACA sRNA populations, in particular of two H/ACA snoRNAs that are guiding 
pseudouridine formation in 18S rRNA (Bellodi, McMahon et al. 2013). Furthermore, the 
authors tested cells from different Dyskeratosis congenita patients and different tissues 
and found that H/ACA sRNA levels were different across tissues. Then researchers 
transfected cells with WT Dkc1, which induced H/ACA sRNA transcription to reach 
almost normal levels. When they tested pseudouridine levels in rRNA in these cells, they 
discovered that indeed specific pseudouridines were reduced in rRNA corresponding to 
the down-regulated guide H/ACA sRNA. Moreover, the ability of hematopoietic cells to 
differentiate was rescued by introducing WT Dkc1 (Bellodi, McMahon et al. 2013). The 
observation that H/ACA sRNAs are tissue specific raises the question of whether the 
function of H/ACA sRNAs in pseudouridine formation is vital or whether these H/ACA 
sRNAs are involved in other hematopoiesis-related functions in these particular cell 
types.  
 
1.3.5 Stem cell biogenesis 
There are many types of stem cells such as for example uMSC (human umbilical cord 
blood derived mesenchymal stem cells). This type of pluripotent stem cell can 
differentiate into many types of cells, which makes it a very good candidate for cell-based 
therapy. In this particular cell line, one type of H/ACA snoRNA (SNORA7A) is crucial 
for regeneration of the cells as well as their differentiation abilities. When SNORA7A 
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expression is reduced using siRNAs, uMSC severely fail to proliferate. And when 
researchers compromised the structure of SNORA7A by expressing SNOR7A with a 
mutation that prevents it from binding to the H/ACA proteins, the uMSC cells fail to self-
renew and differentiate (Zhang, Xu et al. 2016). Interestingly, Dkc1 seems to be 
important for the H/ACA sRNA to fulfill its function in these cells (Zhang, Xu et al. 
2016). 
 
1.3.6 H/ACA snoRNAs and chromatin 
A significant population of snoRNAs such as ACA44 has been found to stably interact 
with chromatin in human cells and Drosophila cells (Schubert, Pusch et al. 2012). These 
snoRNAs are enriched within chromatin-associated RNAs. Our understanding of the 
functional role of these particular H/ACA snoRNAs for chromatin is still limited. Another 
type of noncoding RNA known as C/D snoRNA associates with chromatin binding 
protein Df31 and promotes the open state of chromatin. Therefore, it is possible that 
H/ACA snoRNAs are also conducting similar functions as well (Schubert, Pusch et al. 
2012, McMahon, Contreras et al. 2015). Surprisingly, the interaction of the H/ACA 
snoRNAs with chromatin is independent from the H/ACA proteins. Scientists did not 
detect any of the protein complexes associated with chromatin by mass spectrometry. 
This study provides new evidence that H/ACA sRNAs could participate in cellular 
functions independently from their canonical protein complex (Schubert, Pusch et al. 
2012). If H/ACA sRNAs are able to perform different cellular functions, they could 
potentially have other protein partners that enable them to do so.  
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1.3.7 H/ACA sRNAs and micro RNAs 
Interestingly many H/ACA snoRNAs that are involved in rRNA biogenesis can serve as 
precursors for much smaller RNAs that behave like microRNAs of which many are 
conserved among eukaryotes including humans (Scott, Avolio et al. 2009, Taft, Glazov et 
al. 2009). These RNAs are “like” microRNAs in the sense that they get processed mostly 
from the 3’ hairpin of H/ACA sRNAs by Dicer and are associated with Ago1 and Ago2 in 
humans (Ender, Krek et al. 2008). The latter proteins form complexes with H/ACA 
scaRNA-like miRNAs and control gene expression at the post-transcriptional level 
(Ender, Krek et al. 2008). In addition, further investigations at the genomic level of 20 
microRNAs in humans revealed that they have evolved from H/ACA snoRNAs. Five 
members of these microRNAs are found to bind to Dkc1 (Scott, Avolio et al. 2009). It is 
not clear whether snoRNA-like microRNAs are the byproduct of H/ACA sRNAs 
degradation or whether they possess additional functions. One proposed mechanism 
hindering H/ACA RNA-like microRNA transcription is hypermethylation of the gene 
(Ferreira, Heyn et al. 2012, Lopez-Serra and Esteller 2012).  
 
1.3.8 Small Cajal body-specific RNAs targeting snRNAs 
In eukaryotes, the majority of mRNAs are transcribed as pre-mRNAs that undergo 
maturation by removal of introns either by self-cleavage or by the spliceosome. The latter 
constitutes a massive RNP structure of almost 100 proteins and five snRNAs (U1, U2, 
U4, U5 and U6). U2 snRNA is exceptionally important as it contains a region to interact 
with the pre-mRNA intron. U2 is heavily modified, and the bulk of the nucleotide 
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modifications are pseudouridines that represent about 60% of the total modifications (Yu, 
Ge et al. 2011). This heavily-modified region is the branch site recognition region and 
contains three conserved pseudouridines. These pseudouridines are important for the 
accurate structure of U2 snRNA as well as for activation of the ATPase activity of one of 
the proteins that is implicated in the splicing mechanism (Wu, Adachi et al. 2016). Many 
pseudouridines are also found in regions of U6 and U4 that are important for base paring 
as well as in the U6 catalytic core (Wu, Yu et al. 2011). Although some of these 
pseudouridines are introduced by standalone pseudouridine synthases, some 
pseudouridines, which are conserved and also play fundamental roles in the spliceosome 
machinery, are generated by H/ACA scaRNP complexes. These guide H/ACA sRNAs 
reside in Cajal bodies, and they are structurally very similar to H/ACA snoRNAs with 
only a slight difference as they contain a CAB signal for localization (Marz, Gruber et al. 
2011).  
 
1.3.9 Intron-derived noncoding RNAs with snoRNA ends (sno-IncRNAs) 
The class of H/ACA sno-IncRNAs is poorly studied. Members of this class are found to 
be tissue specific, conserved and expressed in humans and monkeys (Zhang, Yin et al. 
2014). A group of these sno-IncRNAs are flanked by H box sequences at their 5’ end and 
ACA box sequences at the 3’ end. It is not known yet if these RNAs bind to the same 
H/ACA proteins or to other proteins. The function of these sno-IncRNAs remains 
unexplored as well (Baker 2011, Zhang, Yin et al. 2014).  
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1.3.10 Intronic AluACA RNAs 
About 10% of the human genome is encoding a subclass of H/ACA sRNA known as 
AluACA RNA. Despite this massive occupancy in the human genome, the functional role 
of AluACA RNAs is still unclear. Strikingly, expression of AluACA RNA is extremely 
low, and it is not fully known if the level of expression is coupled to stress. Mature 
AluACA RNAs successfully bind to the H/ACA proteins (Jády, Ketele et al. 2012, 
Ketele, Kiss et al. 2016).  
 
1.3.11 Ribosome biogenesis and the contribution of H/ACA snoRNPs 
In the nucleolus, ribosomal RNA is transcribed as a massive precursor (pre-rRNA) that is 
comprised of the mature rRNA sequences (18S, 5.8S and 25S/28S rRNA) along with the 
internal (ITS1 and ITS2) and external (5’ ETS and 3’ ETS) transcribed spacers that have 
to be excised (called rRNA processing). Many trans-acting factors are involved in pre-
rRNA processing and maturation including hundreds of H/ACA snoRNPs that catalyze 
isomerization of target uridines to pseudouridines. H/ACA snoRNPs are involved in the 
early stages of ribosome biogenesis in the nucleolus. During transcription or shortly after 
transcription, 18S rRNA can be processed from its precursor 20S pre-rRNA through 
cleavage at three distinct sites. One of the factors involved in this process belongs to the 
class of H/ACA snoRNPs. Specifically, one highly conserved and essential factor for cell 
viability is an RNA known as U17 (human) or snR30 (yeast) that belongs to H/ACA 
snoRNA class. This particular H/ACA snoRNA has no known target uridine in all 
ncRNAs including pre-rRNA, but it guides the H/ACA snoRNP complex to defined 
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sequences in the pre-35S rRNA (Morrissey and Tollervey 1993, Kiss, Jady et al. 2004). 
Although it is not clear how snR30 facilitates processing of pre-18SrRNA, it has been 
found that pre-18S rRNA fails to be processed at sites A0, A1 in the 5’ ETS region and 
A2 sites in the ITS1 region in absence of snR30 or with snR30 mutated at the 3’ hairpin 
that prevents direct base pairing to pre-rRNA. As snR30 is essential for pre-rRNA 
processing, any defect in this H/ACA snoRNA completely abolishes 18S rRNA 
accumulation (Fayet-Lebaron, Atzorn et al. 2009). SnR30 is one of the longest members 
of the H/ACA sRNA family as it contains about 600 nucleotides. It folds into a secondary 
structure that resembles the consensus 5’hairpin-hinge-hairpin-3’tail in H/ACA sRNA but 
with an additional middle hairpin (Atzorn, Fragapane et al. 2004). Further structural 
analysis of snR30 was conducted revealing that the most important regions that are 
needed for snR30 to fulfill its function are contained within the 3’ hairpin (Atzorn, 
Fragapane et al. 2004).  
Maturation of rRNA also involves numerous nucleotide modifications. Over 100 uridines 
in rRNA sequences are known to be the canonical targets for a number of H/ACA 
snoRNAs. The latter directly base pair with the target rRNA sequence which allows the 
H/ACA snoRNP complex to pseudouridylate a very distinct uridine (Ni, Tien et al. 1997, 
Kiss, Jady et al. 2004). About 8-10% of the total uridines in human 25S rRNA and 18S 
rRNA are isomerized to pseudouridines (Lestrade and Weber 2006). All these 
modifications in the target rRNAs are exclusively introduced by H/ACA snoRNPs. 
Although the target uridine is not necessarily conserved among eukaryotes, interestingly 
the general locations of pseudouridines in rRNA are conserved as pseudouridines are 
found in rRNA regions that are critical for ribosomal function. For example, the peptidyl 
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transferase center (PTC), the A, P and E sites as well as the A- site finger region, the 
decoding region, and also important helices that form inter-subunit bridges such as Helix 
69 are rich in pseudouridines (Liu, Liang et al. 2008, Baudin-Baillieu, Fabret et al. 2009). 
Ribosome biogenesis is upregulated in cancer while on the other hand alterations in 
ribosome biogenesis give rise to inherited disorders (Montanaro, Treré et al. 2012, 
Ruggero and Shimamura 2014). 
Bacterial rRNA has relatively few pseudouridines and their absence does not affect 
bacterial survival as all stand-alone, ribosomal pseudouridine synthases are non-essential 
in bacteria. However, the number of pseudouridines is drastically increased in highly 
complex organisms which may aid the ribosome to conduct a broader range of functions 
(Ruggero, Yoon et al. 2007, Piekna-Przybylska, Przybylski et al. 2008). For example, the 
Dyskeratosis congenita disorder is characterized by a reduction in pseudouridine levels in 
the rRNA which is not tolerated in other tested eukaryotic organisms including mouse 
(He, Navarrete et al. 2002). Ribosomes with reduced levels of pseudouridines are not able 
to translate a unique set of mRNAs with regulatory elements known as internal ribosome 
entry sites (IRES) (Blazewicz, Barnard et al.). These types of mRNAs are encoding for 
factors that initiate crucial cellular events such as apoptosis and tumor suppressors (Yoon, 
Peng et al. 2006, Jack, Bellodi et al. 2011, Penzo, Rocchi et al. 2015). The fact that the 
ribosome’s functional ability is changed in response to pseudouridine formation makes it 
tempting to speculate that specific ribosomes could be dynamically involved in gene 
expression (Xue and Barna 2012). In this respect, it is noteworthy that many H/ACA 
snoRNAs, that have been involved in pre-rRNA pseudouridylation, are either up- or 
down-regulated in many types of cancer (Ronchetti, Todoerti et al. 2012, Mannoor, Shen 
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et al. 2014).  
The Fournier lab examined how preventing pseudouridine formation in particular regions 
of rRNAs affects yeast cells. First, overall elimination of pseudouridine in yeast rRNA by 
making inactive Cbf5 is not well tolerated, as cells were growing only at 25 °C albeit very 
slowly (Zebarjadian, King et al. 1999). The group further eliminated pseudouridine 
formation at particular sites in the rRNA by deleting individual or groups of H/ACA 
snoRNAs, for example RNAs targeting helix 69 in 25S rRNA containing five 
modifications (three are in the loop and two are in the stem). When these pseudouridines 
are deleted in combination, the ribosome structure was altered and the translational read-
through of stop codons increased (Liang, Liu et al. 2007).  
In addition, examination of cells obtained from X-DC patients shows that a particular 
H/ACA sRNA (SNORA15) that directs pseudouridylation in 18S rRNA at position 
U1367 is expressed only at very low levels and thus the modification is also decreased at 
that position (Bellodi, McMahon et al. 2013). However, there is currently no clear 
explanation for how deregulation of few a subsets of H/ACA snoRNAs is contributing to 
the disease Dyskeratosis congenita. On the other hand, some H/ACA sRNAs that guide 
pseudouridylation in 18S rRNA such as H/ACA snoRNA42 are up-regulated in solid 
tumors (Bellodi, McMahon et al. 2013).  
 
1.3.12 H/ACA sRNPs acting on messenger RNAs 
Discovering that pseudouridines are also found in mRNA has shifted our perspective 
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about this modification (Carlile, Rojas-Duran et al. 2014, Lovejoy, Riordan et al. 2014, 
Schwartz, Bernstein et al. 2014). Using novel sequencing techniques described above, 
over 2000 pseudouridine sites were identified in human mRNA (Li, Zhu et al. 2015). 
Although some uridines in mRNA are isomerized by H/ACA sRNPs, the majority of 
pseudouridines seems to be introduced by standalone pseudouridine synthases (Schwartz, 
Bernstein et al. 2014). Many mRNAs in yeast have been identified that are 
pseudouridylated in normal conditions, and the number of pseudouridines further 
increases upon stress such as heat shock (Schwartz, Bernstein et al. 2014, Abidi, Sayari et 
al. 2016). So far the majority of the pseudouridines that have been detected in the mature 
mRNA are located within the translated sequences (open reading frame). Moreover, only 
a few pseudouridines are found in the 3’ UTR and only in very rare cases in the 5’ UTR 
(Lovejoy, Riordan et al. 2014). Artificial introduction of pseudouridines at the first 
position in a stop codon impairs termination of translation in both in vivo as well as in 
vitro, and these stop codons with pseudouridines are translated into serine and threonine 
for AA and AG, and phenylalanine and tyrosine for GA (Karijolich and Yu 2011). 
This finding suggests not only that pseudouridine can change the genetic code, but it 
could also regulate gene expression. The crystal structure of the ribosome shows the 
tRNA anticodon forming non-canonical interactions with AG in mRNA (Fernández, Ng 
et al. 2013). Further investigations are needed to delineate the consequences of 
pseudouridines in mRNA for gene expression and regulation thereof.  
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Chapter 2. Objectives 
The exact effects of Dyskeratosis congenita mutations on ribosome biogenesis have not 
been identified yet. Interestingly, the symptoms of Dyskeratosis congenita are varied and 
the severity of the syndrome is somewhat dependent on the location of the mutation. 
Here, I wanted to characterize yeast strains that each have a single Dyskeratosis congenita 
mutation. Yeast is a model organism that is used extensively by many researchers to 
better understand for instance a common pathway or to investigate the function of a 
protein in eukaryotes as it is much simpler than higher eukaryotes and much easier to 
work with. First, I planned to generate six haploid S. cerevisiae yeast strains by taking 
advantage of the homologous recombination mechanism. Three of the selected mutations 
are located within the catalytic domain of Cbf5, two in the PUA domain and one in the 
unstructured C-terminal extension of Cbf5. Second, I aimed to assess the growth behavior 
to screen for phenotypes in these strains. Subsequently, I planned to examine Cbf5p 
expression levels among mutant strains to see if there is any difference indicating reduced 
protein stability compared to the wild type. Finally, it was my objective to investigate cell 
cycle progression in these strains. 
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Chapter 3 Materials and Methods 
 
3.1 Site-directed mutagenesis  
Overlapping primers for each mutation were designed and the annealing temperature for 
each set of primers was adjusted in each PCR reaction (Table 1). The PCR reaction (20 
L total) contained Q5 DNA polymerase (NEB) and its corresponding buffer, 25 mM 
MgCl2, 0.4 mM dNTPs, 0.5 M forward and reverse primers each, 10 ng/L of DNA 
template (pUC19-ScCbf5-YIp5). The PCR program was the following, (1) initial 
denaturation at 98°C for 30 s, (2) denaturation at 98°C for 10 s, (3) annealing & extension 
at 72°C for 6 min, (4) final extension at 72°C for 6 min and finally hold at 4°C. Steps (2) 
and (3) were repeated for 30 cycles. The PCR product was digested with DpnI (1 U/L, 
Fisher Scientific) overnight at 37°C. Samples were analyzed by 1% agarose gel 
electrophoresis, stained with ethidium bromide and visualized with UV light (260 nm).  
Table 1: Overlapping primers that have been designed to implement the desired mutation 
together with the corresponding annealing temperatures.  
cbf5 
mutation  
Forward primers (5` to 3`) Reverse primers (5` to 3`) Annealing 
temperature  
S91G GGTCACGGTGGTACATT
GGATCCAAAAGTTACAG 
CAATGTACCACCGTGAC
CAGTCTTCTCACAAC 
72°C 
R128W GTATTGTCTGGTTGCAT
GATGCTTTGAAGGATG 
CATGCAACCAGACAATA
CACACATACTCCTTACC 
71°C 
S250R GAACGTTACTTGAGATC
CATTATTCAACC  
GGATCTCAAGTAACGTT
CATCTCTTGTATTGTCG  
67°C 
K284R GGTGCAAGGTTGATGAT
CCCTGGTTTATTGCG 
GATCATCAACCTTGCAC
CATAACATACTGCATTG
AC 
72°C 
M320T CGCACAAACGTCAACCG 
TTGACTTAGCTTCCTG 
CGGTTGACGTTTGTGCG 
ATGGCAACG 
72°C 
G372E GGATAAATACGAGCGTG 
TTAACGAAAACACCCCA 
G 
CACGCTCGTATTTATCCA 
ATTTGCCGTCTGC 
72°C 
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3.2 Chemical Transformation into E. coli DH5competent cells. 
1.8 L (20-60 ng/L) of the mutagenesis PCR product or of a ligation reaction was 
transformed into 20 L of highly competent E. coli DH5 cells (New England Biolabs). 
After addition of the DNA to the cells, the mixture was incubated on ice for 30 min 
followed by heat shock at 42°C for 45 s. After incubating on ice for 1 min, 250 L LB 
medium was added and the reaction was incubated with shaking at 37°C for 1 hour. The 
transformation mixture was then plated onto LB agar containing 100 mg/mL ampicillin 
followed by incubation of the plates for 12-16 hours at 37°C.  
 
3.3 Preparation of Glycerol Stocks 
Selected colonies were used to inoculate a 5 mL liquid LB-Amp culture which was 
incubated 37°C for 16 hours. 750-900 L of the culture was used to make glycerol stocks 
by adding the culture to 500 L autoclaved glycerol followed by vortexing and shock 
freezing in liquid nitrogen. Glycerol stocks were stored at -80°C. 
 
3.4 Miniprep of plasmid DNA 
3-4 mL of an overnight E. coli culture were used to plasmid using a Miniprep Kit from 
Biobasic (following the manufacturer’s instructions for high copy plasmid extraction).  
 
3.5 Sequence confirmation 
Plasmids were sent to GENEWIZ for sequencing using primers that are located about 120 
base pairs upstream or downstream of the mutation site. The resulting sequence was 
aligned to the wild-type sequence of CBF5 using the online sequence alignment tool 
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CLUSTALW to identify positive mutants. The sequence of the whole gene was examined 
to ensure the absence any other mutations.  
 
3.6 Plasmid restriction, gel extraction and dephosphorylation 
To isolated the mutated cbf5 gene, the pUC19-ScCbf5-YIp5 plasmids (1.6 ng/L) were 
digested for 4 hours with EcoRI and SalI (2 U/L, Fisher Scientific) in Orange buffer at 
37°C. YIp5 plasmid was digested using the same conditions. The digestion products were 
separated by 1% agarose gel electrophoresis. The bands that correspond to the length of 
cbf5 were excised from the gel, and the DNA was purified using an EZ-10 Spin column 
DNA Gel Extraction kit from Biobasic according to the manufacturer’s instructions. The 
linear YIp5 vector was then dephosphorylated with shrimp alkaline phosphatase (1 U/L, 
Fisher Scientific) in SAP buffer for 1 hour at 37°C. Subsequently, the enzyme was 
deactivated by heating the reaction at 65°C for 20 min.  
 
3.7 Sticky-end ligation 
To ligate the isolated cbf5 insert to the linear, dephosphorylated YIp5 vector, insert and 
vector were mixed at a molar ratio of 4:1 insert to vector with T4 DNA ligase (2 U/l, 
Fisher Scientific) and its complement buffer in 20 L total reaction volume. The reaction 
was incubated at 16°C for 24 hours. The next day, after deactivation of the ligase 
enzymes by heating at 65°C for 20 min, about 1.8 L of the ligation product was 
transformed into E. coli DH5competent cells as described above.  
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3.8 Restriction of YIp5-ScCbf5 
We have induced a single cut in ScCBF5 using BshTI for cbf5 K284R, M320T and 
G372E or HpaI (KspAI) for cbf5 S91G and R128W and BamHI for S250R. In brief, 1.5 
ng/L of plasmid were incubated with 2 U/l restriction enzyme (Fisher Scientific) in a 
total volume of 20 L for 60 min at 37°C. Subsequently, restrictions enzymes were heat 
inactivated by incubation for 20 min at 80°C for BashTI similarly for BamHI and at 65°C 
for HpaI.  
 
3.9 Yeast Transformation  
First, S. cerevisiae BY4741 cells were made competent as follows. This strain is a 
laboratory strain derivative of S288C with mating type MATa and genotype his31 
leu20 met150 ura3A single BY4741 yeast colony was selected for growth in 5 mL 
YEPD medium with 2% glucose for 5-7 hours at 30 °C and 200 rpm shaking. About 
2.5x10
8
 cells of this culture were used to inoculate a 50 mL culture in YPDE + 2% 
glucose. Growth was monitored by counting using a hemacytometer, and once the culture 
reached the exponential phase at 2 x 10
6 
cells/mL, the cells were harvested by 
centrifugation at 3000g for 5 min. Next, the cells were resuspended in 25 mL distilled 
water and washed twice by centrifugation. Then the cells were washed once with 10 mL 
of SORB buffer (100 mM LiOAc, 10 mM Tris-HCL pH 8.0, 1 mM EDTA/NaOH PH 8.0, 
1 M sorbitol) and centrifuged gently. The cells were resuspended in 360   SORB and 
40 L DNA carrier (10 mg/mL Salmon sperm DNA). Finally, 50 L aliquots of the 
competent yeast cells were prepared, shock frozen in liquid nitrogen and stored at -80°C.  
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The linearized YIp5-Sccbf5 plasmid (1-2 ng/L) was mixed with 50 L competent 
BY4741 cells, and 40% PEG solution was added and mixed via vortexing. The reaction 
was left at room temperature for 30 min, then a total of 10% DMSO was added, and the 
transformation mixture was subjected to heat shock at 42°C for 20 min. Subsequently, 
cells were collected through centrifugation and gently resuspended in 200 L of S-broth. 
Finally, the transformation mixture was plated onto two Sc-ura+ 2% glucose plates. The 
plates were then incubated at 30 °C for 48 hours.  
 
3.10 Preparation of S. cerevisiae glycerol stocks 
Colonies are selected and grown in 5 mL Sc-ura+ glucose medium at 30°C. At the mid of 
exponential phase of about 0.4 - 0.7 OD600, and 750 L of the cultures was collected to 
make a glycerol stock by mixing with 250 L autoclaved glycerol in a cryo-vial. The cell 
suspension was shock frozen in liquid nitrogen, and the glycerol stock was stored at -
80°C. (Growth of the remaining culture was continued to grow over night to harvest cells 
for genomic DNA extraction.)  
 
3.11 Genomic DNA extraction and PCR amplification of ScCbf5 
Genomic DNA from yeasts cells was extracted by using Geneaid-Presto Mini gDNA 
Yeast Kit from FroggaBio Scientific Solution following the manufacturer’s instructions. 
The gDNA that was extracted was visualized by 0.75% agarose gel electrophoresis. A 
total of 25 L PCR reaction was prepared by adding 10-130 ng/L of genomic DNA, 10x 
Pfu DNA polymerase buffer, 0.5 M each of the forward primer (EcoR1-ScCbf5-up) and 
the reverse primer (YIp5 downstream SalI reverse), as well as 0.4 mM dNTPs. The 
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reaction was incubated in the thermocycler using the following program: initial 
temperature 95°C for 5 min, denaturation at 95°C for 30 s, annealing at 52°C for 30 s and 
synthesis at 72°C for 2.5 min, final extension at 72°C for 7 min and hold at 4°C. The PCR 
product was visualized via agarose gel electrophoresis. All PCR products representing 
successful amplification of ScCbf5
 (+mutation)
 were analyzed by Sanger sequencing using 
primers that detected the mutations as well as primers that span the whole ScCbf5 gene to 
ensure that there are no other mutations. The primers that were used in the PCR reaction 
as well as for sequencing are listed in Table 2. The location of the primers is illustrated in 
Figure 5.   
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Table 2: Primers that were used in the PCR reaction to amplify cbf5 or for sequencing.  
Primer Name 
(abbreviation used in 
Fig. 5) 
Sequence (5` to 3`) 
EcoR1-ScCbf5-up 
(EcoR I Fw) 
AATTCATGTCAAAGGAGGATTTCGTTAT 
SalI-ScCbf5down(Sal 
I down) 
GTCGACGGAATGCAATAATCGGCGATAT 
ScCbf5 seq 1038 
antisense (1308 rev) 
GGACCCAAACCCCATCTTCTTGGG 
ScCbf5 seq 562 
antisense (562 rev) 
GCATATAAGTACCAGCTTCACAGGAAGC 
YIp5 downstream 
SalI reverse (YIp5-Sal 
I down) 
CAGTCATAAGTGCGGCGACG 
ScCbf5 seq sense 976 
(976 fw) 
GCTTCCTGTGATCATGGTGTTGTTGC 
Yeast Cbf5 antisense 
HindIII (anti-Hind III 
rev) 
AAGCTTTCATTTCTTAGATTTCTTAGATTTC 
YIp5 integration 
Cbf5(C) reverse 
(YIP5 Cbf5(c) rev) 
CCTCAGAATCACCGTCTTCAG 
  
YIP5 integrated Amp 
forward 
ATAATACCGCGCCACATAGC 
 
  
Figure 5: Location of primers used for PCR reaction or used for mutation confirmation. 
The CBF5 gene is shown in gray and the promoter sequence in light yellow. The location 
of the mutations is depicted above the gene while the name of the primers is indicated 
underneath.   
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3.12 5-Fluoroorotic Acid (5-FOA) Pop-out procedure 
SD+Ura+5-FOA plates were prepared by adding 136 mL S-broth, 0.288 g SC-ura, 2.4 g 
agar in a total volume of 150 mL distilled water. The mixture was then autoclaved, and 
while the mixture was still hot, 5.7 mM 5-FOA was added. Right before pouring into 
plates, 6 mL of 50% w/v glucose and 2 mg/mL uracil were added and mixed gently.  
Yeast strains were streaked on SD-ura plates, and one colony was selected and incubated 
in 5 mL YEPD liquid culture for about 7-8 h until the cells reached the exponential phase 
(0.4 OD600) at 30°C with shaking at 200 rpm. The cells were collected via centrifugation 
at 3000 xg for 5 min, then the cells were resuspended in YEPD to 5x10
8
 cells/mL. Serial 
dilutions of 1x10
6 
 and 1x10
7
 cells/mL were made to be plated on 5-FOA plates. The 
plates were incubated at 30°C for 48 h. Following the pop-out, genomic DNA was 
prepared of selected colonies as described above, the Cbf5 gene was amplified using the 
primers “EcoR1-ScCbf5-up” and “YIp5 downstream SalI reverse”, and the PCR products 
were sequenced. 
 
3.13 Growth analysis 
To analyze growth in liquid medium, yeast strains were streaked onto YPDE + 2% 
glucose plates, and allowed to grow for 48 hours at 30°C. Three colonies from each strain 
were selected and grown in 5 mL YPDE + 2% glucose medium at 30°C and 200 rpm 
shaking for 5 hours. For each colony, three technical replicates were generated by 
preparing three dilutions (from each colony) of 1x10
6
 of cells/130 L of YPDE + 2% 
glucose. Each dilution was placed into one well in a 96-well plate; as blank, YPDE+ 2% 
glucose was used. The microplate reader from BioTek with Gene5 software was used in 
this assay with shaking at 250 rpm and measurement of the OD600 every 15 min for 60 h. 
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This experiment was conducted at 30°C, 18°C and at 37°C. To analyze growth at 18°C, 
the plate reader was placed into a refrigerator at 14°C to make sure that the temperature 
will be stable at 18°C. The data is then exported as an Excel sheet and further analyzed in 
Excel, and the figures were made using the Prizm software. First, the average for the four 
technical replicates was calculated. Next, I calculated for each biological replicate (based 
the average of the technical replicates) the value ln(A0/At) for each time point t where ln 
is the natural logarithm, A0 is the OD600 reading at time zero (start time), and At is the 
OD600 at time t. Subsequently, ln(A0/At) was plotted against time (in minutes), the linear 
region was selected and fit to a linear regression to obtain the slope y. The value of the 
slope y is used in the equation ln(2)/y to get the doubling time in minutes. Lastly, the 
average and the standard deviation of the doubling times of the different biological 
replicates was calculated.  
To analyze growth on solid medium, cells were similarly grown in YPDE + 2% glucose 
until they reached the mid of the exponential phase. The cultures were used to prepare 
serial dilutions of 1x10
3
, 100, 50, 10 and 5 cells per 5 L. The cells were placed in 5 L 
drops onto YPDE + 2% glucose plates, left to dry, and inverted plates were incubated at 
30°C or 18°C or 37°C for 48 - 72 hours. A picture of each was plate was taken with a 
smart phone camera or a Canon camera.  
 
3.14 Whole-cell extract preparation 
Whole-cell extract was prepared from 2 OD600 of cells from an exponentially growing 
culture. After centrifugation of the cell culture at 300 xg for 15 min, the cells were 
resuspended and incubated in 0.4 mM NaOH for 5 min. After a second centrifugation, the 
cells were resuspended in Tris-Urea (0.1 M Tris and 8 M Urea) pH 8 and 10% SDS, 
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boiled for 7 min, and 6x SDS loading dye was added before continuing to boil the 
samples for additional 3 min.  
 
3.15 Western Blotting 
To detect and semi-quantify Cbf5 protein levels, whole-cell extract is separated by 12% 
SDS-PAGE. The SDS-PAGE is subsequently blotted onto nitrocellulose at 100 V for 70 
min in cold transfer buffer (48 mM Tris, 38.7 mM glycine, 10% (w/v) SDS, 20% (v/v) 
methanol). Subsequently, the nitrocellulose membrane is washed twice with 1x TBS 
buffer (50 mM Tris pH 7.6, 150 mM NaCl), and then incubated for 1 hour in blocking 
buffer (2% (w/v) BSA in 1x TBS). The primary antibody used in this assay was a custom-
made antibody from BioBasic Inc.; it was generated by infecting two rabbits with an 
antigen of a 15-residue long, synthesized peptide designed from a sequence at the C 
terminus of Cbf5 (aa 461-475: KKEKKRKSEDGDSEE). A 1:1,000 dilution in 3% BSA 
in TBS of this primary antibody was made, and the blot was incubated with primary 
antibody overnight at 4°C. The next day, the membrane was washed one time with TBS 
buffer followed by three times wash with TBS+TT, then incubated with the secondary 
antibody (horseradish peroxidase coupled anti-rabbit antibody (Sigma), 1:1,000 dilution 
in 3% BSA and 1x TBS) for 1 to 2 hours, and finally washed again with TBS-TT three 
times.  
For detection, the blot was incubated with 25 mL luminol solution (100 mM HCl pH 8.5, 
11.3 mg luminol dissolved in 0.25 mL DMSO and 91.3 mM p-coumaric acid dissolved in 
DMSO) and 15 L of H2O2 solution (40 M H2O2 and 100 mM HCl) and developed for 
5-8 min. A picture of the chemiluminescence was taken with an Amersham Imager 600. 
The membrane underwent mild stripping procedure by washing the membrane twice for 
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10 min with stripping buffer (160 mM glycine pH 2.2, 1 g SDS, 10 mL Tween 20 
dissolved in 800 mL distilled water), followed by washing three times with PBS buffer, 
finally washing twice with TBS-TT for 5 min. The membrane is blocked for one hour 
with 3% PBS and then incubated with 1:1000 PGK1 primary antibody conjugated with 
horseradish peroxidase (Abcam) overnight.   
 
3.16 Propidium iodide staining 
5 mL yeast cultures starting at 0.3-0.4 OD600 in YEPD + 2% glucose were grown in the 
morning for 1-2 hours at 30°C to reach the early exponential growth phase before adding 
15 g/L nocodazole (Calbiochem- EMD Millipore Corp). The culture was incubated for 
additional 2 hours. A second dose of nocodazole (7.5-15 g/L) was added, and the 
culture was incubated for another hour. 3L of culture were observed in a microscope to 
ensure that more than 98% of cells were budding and had reached the G2/M phase. Cells 
were released from the arrest by centrifugation followed by washing twice with pre-
warmed (30°C) water. Next, the cells were resuspended into new pre-warmed (30°C) 
5mL YEPD + 2% glucose. Cell samples of 200 L were collected before nocodazole 
treatment, immediately after nocodazole treatment, 15 min, 1 hour, 2 hours and 3 hours 
after restarting cell cycle by removing the nocodazole. The cells were collected via 
centrifugation, then washed twice with distilled water and resuspended in 4 mL 70 % cold 
ethanol and samples were stored at -20°C. The next day, the cells were centrifuged and 
washed twice with cold Dulbecco’s phosphate buffer saline DPBS buffer (136.9 mM 
NaCl, 26.8 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4 in 1 L distilled water and 
adjusted to pH 7.4). Next, cells were treated with 50 mM NaCl and 50 L of 10 g/mL 
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RNase A for 30 min at 30°C. Cells were centrifuged again and washed with DPBS buffer. 
Subsequently, cells are incubated with 0.5 mL DPBS buffer and 50g/mL propidium 
iodide for at least 10 min.  
 
3.17 Flow cytometry 
Propidium iodide-stained cells were analyzed in a Fluorescence Activated Cell Sorter 
(FACS) from BD Biosciences by exciting at 488 nm and detection at 610 ± 20 nm. In 
addition, the forward (FSC) and side scattering (SSC) was recorded. Cells were injected 
using a 70 m nozzle, and for each sample 50,000 cells were measured. The data were 
analyzed using the Flowing Software to visualize the data on a dot plot (forward and side 
scattering) and also on a histogram (propidium iodide fluorescence). The dot plot data 
was used to select the populations of single yeast cells from cell debris and cell 
aggregates (see Appendix Fig. A2 for gating information). The gating was kept constant 
for all mutants and the wild-type for all time points. 
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Chapter 4. Results 
 
4.1 Site-directed mutagenesis 
Site-directed mutagenesis was used to create BY4741 mutant strains each containing a 
single mutation within the genomic CBF5 gene. All of the mutations that have been 
selected are within regions that are conserved between yeast CBF5 and human DKC1. 
Moreover, the mutations correspond to the ones that have been documented in the human 
disorder, Dyskeratosis congenita. The mutations encode amino acid substitutions within 
either the catalytic or PUA domains of CBF5 or in the unstructured C-terminus (Figure 
6). The ones that are located in the catalytic domain are S91G, R128W, and S250R which 
correspond to T121G, R158W and S280R in humans, respectively. The mutations that lie 
within the PUA domain are K284R, and M329T and the corresponding mutations in 
human are K214R, and M350T (Figure 6). Lastly, the mutation G372E resides in the 
unstructured C-terminal region of the Cbf5 protein and corresponds to G402E in humans. 
Most importantly, these mutations result in disease phenotypes ranging from severe to 
very severe. The majority of the mutations within the catalytic domain causea more 
severe disease than the ones within the tail region (Dokal 2000, Marrone, Walne et al. 
2005, Dokal 2011). We hypothesized that these mutations are likely to have an effect on 
the S. cerevisiae model organism. In addition, patients with these mutations often develop 
different types of cancer as the disease progresses, a feature of Dyskeratosis congenita 
that we would like to study in the future.  
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Figure 6: Location of Dyskeratosis congenita substitutions mapped onto the 
crystal structure of ScCbf5p (PDB:3U28). Within the catalytic domain are 
displayed in the following colors: S91G in yellow, R128W in orange and S250R 
in pink. The mutations in the PUA domain are shown as follows: K284R in green 
and M320T in purple. The last mutation G372E is within the unresolved C-
terminal region.  
 
There are two stages of generating yeast strains harboring mutations in the genomic 
CBF5 gene: the first one is carried out in E. coli, while the second stage is carried out in 
yeast. Initially, this project started with site-directed mutagenesis of the pUC19-
ScCBF5+downstream plasmid which contains the entire CBF5 coding region flanked by 
33 nt upstream and 348 nt downstream of the coding region. This was followed by 
sequence validation to assure the integrity of the CBF5 gene and also successful 
mutagenesis (Figure 7). As shown in Figure 7, three samples were collected at different 
time points: 1) before starting the PCR reaction, 2) after the PCR and 3) after overnight 
DpnI digestion. Before the initiation of the PCR reaction, the plasmid migrates similarly 
to the 3500bp ladder band, even though pUC19-ScCBF5-downstream is 4100 bp in size; 
45 
 
this is because the plasmid is supercoiled and travels much faster than a linear DNA. 
After the PCR reaction, the successful mutagenesis product appears as a band much 
higher than the size of the supercoiled DNA template because the plasmid is linearized 
and not supercoiled and thus traveled corresponding to its length of 4100 bp. The control 
reaction does not contain DNA polymerase; therefore the after-PCR band corresponds to 
the original size of the DNA template. Unsuccessful mutagenesis is evident for the 
mutations S91G and G372E as no products appear on the agarose gel after the PCR 
(Figure 7); these mutagenesis reactions were later repeated. Next, PCR products are 
subjected to DpnI digestion to ensure that no parent DNA template is left in the reaction. 
DpnI cuts at the GATC sequence only when the A is methylated, and parental DNA 
(purified from E. coli) is methylated unlike the PCR-amplified DNA.  
 
Figure 7: PCR reaction for site-directed mutagenesis of Cbf5 analyzed by agarose 
gel electrophoresis. Site-directed mutagenesis of pUC19-ScCBF5. Mutagenic 
primers were used in a PCR reaction to encode the amino acid substitutions in 
CBF5 indicated at the bottom of the figure. A control PCR was carried out 
without DNA polymerase. After the PCR, the template plasmid was digested by 
DpnI. Samples before and after PCR as well as after the DpnI digestion (as 
indicated on the top) were analyzed by 1% agarose gel electrophoresis. 
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The presence of a band after the restriction with DpnI is an indication that the site-
directed mutagenesis most likely is successful. After site-directed mutagenesis, samples 
were transformed into DH5E. coli competent cells, followed by colony screening, 
plasmid extraction and sequencing. 
Next, the cbf5 gene was restricted from pUC19-Sccbf5 and ligated into YIp5 (yeast 
integrating plasmid). YIp5 allows for the initiation of the second stage of the experiment, 
namely the transition from E. coli to yeast. First, ScCbf5
(+mutation)
 was extracted from 
pUC19 by double restriction and then ligated to YIp5 that was also subjected to the same 
double restriction. The ligation reaction was transformed into E. coli DH5 competent 
cells, after which several colonies were selected, the plasmid DNA was isolated, and then 
plasmids underwent double restriction with EcoRI and Sall (Figure 8).  
 
Figure 8: Restriction screening for the successful ligation of representative mutant Sccbf5 
genes into YIp5. After isolating plasmid DNA, the plasmids were double-restricted to 
release the Sccbf5 genes from YIp5. Then the restriction products were analyzed by 
agarose gel electrophoresis. For each cbf5 mutation (indicated underneath the gel), 
several colonies were analyzed as shown above the gel.  
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The restriction products are separated 1% agarose gel which was stained with ethidium 
bromide and visualized at 260nm. The gel shows clearly that all plasmids that have been 
isolated contain the cbf5 gene and the vector YIp5 (Figure 8). Next, a few of them are 
further selected and verified by sequencing. 
A single double-strand cut was introduced into the cbf5 gene within the YIp5-
Sccbf5+downstream plasmid before transforming it into BY4741 yeast competent cells. 
Restriction enzymes that are used for this step are indicated in the method section. The 
location of the cut site depends on the location of the mutation. For example, for the 
mutations in the N-terminal region cbf5 such as S91G, the cut is induced downstream 
from the site of the mutation. For the mutations that are located at the C terminus such as 
G372E, a cut was introduced upstream from that location. This ensures that several 
hundred nt are available on both sites of the cut to pair with the yeast chromosome during 
homologous recombination. Usually we select a distance of at least 130 nt between the 
mutation and the restriction site to minimize the likelihood that the mutation is reversed 
during homologous recombination. The transformation mixture was plated on SD-Ura 
and grown for 48 hours. At this point, the well-known DNA repair mechanism of 
homologous recombination was exploited. When the yeast cell encounters a damaged 
cbf5 gene, it activates a repair mechanism that joins homologous sequences from native 
CBF5 to the cbf5 gene within the plasmid. Thus, the entire plasmid sequence becomes 
incorporated into the yeast genome (Figure 10). The cbf5 sequences were examined by 
PCR using the genomic DNA as template and primers that target the cbf5 gene (Figure 9). 
I used in each PCR either primer set 1) (YIP5 integrated Amp forward & yeast 
Cbf5antiHindIII) which will generate a band ~2300 bp in size, or primer set 2) (YIP5 
integrated Amp forward & YIp5 integration Cbf5(c)reverse) which will produce a band 
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~2200 bp in size or primer set 3) (ScCbf5 EcoRI up & (YIp5 integration Cbf5(c)reverse) 
which will result in a band ~1500 bp in size. The primer set used typically depends on the 
location of the mutation. For example, PCR with either primer set 1) or 2) are used in 
order to get good sequencing results for mutations near the N terminus (mutations in the 
catalytic domain) whereas for the mutation at the PUA domain (near the C terminus) 
primer set 3) was used (or sometimes primer set 4) (ScCbf5 EcoRI up yeast 
Cbf5antiHindIII) and primer set 5) (ScCbf5 EcoRI up SalI-ScCbf5 downstream) which 
generates a band at less than 1800 bp).  
 
Figure 9: PCR screening of yeast strains after integration of YIp5-Sccbf5 plasmids. 
Genomic DNA was prepared from yeast cells and used as a template in a PCR reaction to 
amplify the cbf5 gene. The PCR products were analyzed on a 1% agarose gel with the 
type of mutation indicated below and the colony number above the gel. Subsequently, 
PCR products were sequenced for confirmation of the mutation. The primers used in this 
reaction (ScCbf5 EcoRI up & YIp5 integration Cbf5(c) reverse) are indicated with blue 
dots in Figure 10. 
 
PCR products that corresponded to the size of cbf5 were sent for sequencing for 
validation. Due to the presence of two cbf5 genes at this stage which were both amplified 
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by the used primers, sequencing results were of poor quality and mutation sites typically 
exhibited two nucleotide peaks in the sequencing chromatogram.  
Naturally, the yeast cells containing an integrated plasmid may rarely eliminate this 
sequence by undergoing a second homologous recombination step. Cells that have 
undergone this step are differentiated from cells that have not by plating yeast cells on 
SD+Ura+5FOA. All cells that did not eject the plasmid sequence from its genome will 
still have the URA3 gene in its genome. The URA3 gene encodes for an enzyme that can 
use 5FOA as precursor to make 5-fluorouracil which is lethal to the cell. In contrast, cells 
that already underwent the pop out will not be harmed by 5FOA and will survive by 
consuming the uracil that has been added to the medium. This process is known as 5FOA 
Pop-out, which is described in the schematic below (Figure 10). 
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Figure 10: Schematic overview of generating mutations in the chromosomal CBF5 gene. 
Upon transformation of the linearized YIp5-Sccbf5 plasmid into S. cerevisiae, the first 
homologous recombination leads to full integration of the YIp5-Sccbf5 plasmid into the 
yeast genome. Subsequently, we selected cells that underwent the second homologous 
recombination (pop-out) by plating the strains on SD+Ura+5FOA. The green and blue 
dots are primers that were used to amplify cbf5. The primers that correspond to the green 
dots are (YIp5 integrated Amp forward & YIp5 integration Cbf5(c)reverse) whereas the 
primers that correspond to the blue dots are (ScCbf5 EcoRI up & YIp5 integration 
Cbf5(c) reverse). 
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The SD+Ura+5FOA plates always exhibited four types of colonies: large colonies, 
medium-sized colonies, relatively small and extremely small colonies. Ten colonies from 
each of the first three categories were selected and genomic DNA extraction was 
performed. A PCR reaction was conducted using primers are indicated in (Figure 11) that 
target CBF5, and the PCR product was visualized on a 1% agarose gel (Figure 11). Next, 
the PCR products were sent for sequencing for verification. Usually, all the sequencing 
results of PCRs performed on large colonies yielded a wild-type sequence. However, 
colonies of medium sized or small colonies almost always contained the mutated cbf5 
gene. Moreover, the sequencing results showed only one peak in the sequencing 
chromatogram at the site of the mutation.  
 
Figure 11: PCR screening of yeast strains potentially containing mutant cbf5 
alleles after the popout of YIp5 vector sequences. Yeast genomic DNA was used 
as a template in a PCR reaction to amplify the cbf5 gene including parts of the 
promoter sequence; the PCR reactions were analyzed by 1% agarose gel 
electrophoresis. As an example, the screening of the cbf5 K284R strain is shown 
here; the different colonies tested are indicated above the gel. Primers used in this 
reaction are ScCbf5 EcoRI up & YIp5 integration Cbf5(c)reverse. 
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4.2 Phenotypic screening 
Growth analysis studies are one of the most widely used experiments for phenotype 
detection in yeast. Therefore, a 96-well plate and plate reader system was used to examine 
yeast cell growth at 18°C, 30°C and 37°C. Three selected colonies were each incubated in 
5 mL YEPD culture. Once the cells reached the middle of the exponential growth phase 
(0.4 OD600), the cells were diluted to 0.1 OD600, placed in a well of the plate and 
incubated with shaking for 60-72 h. At 30°C, the doubling time for the wild type cells 
was about 100 min. The doubling time for each mutant was then compared to the wild 
type to examine any differences in growth rate. None of the mutants grew slower than the 
wild type cells given the standard deviations. Therefore, it was concluded that there are 
no notable differences between the wild type and the mutant strains regarding their 
growth at 30°C in YEPD medium. This experiment was repeated at low and high 
temperatures to investigate the presence of any phenotypic features at suboptimal 
conditions. First the same experiment was repeated at 37°C for 72h. 
 
Table 3: Summary of the doubling time for the WT and the cbf5 mutant strains at 18°C, 
30°C and 37°C. Cells were grown in liquid rich medium for 30 -72 h. The growth test 
was conducted using a plate reader and a 96-well plate. 
 18°C 30°C 37°C 
Muta-
tion 
Doubling 
time, min 
Standard 
deviation, 
min 
Doubling 
time, min 
Standard 
deviation, 
min 
Doubling 
time, min 
Standard 
deviation, 
min 
WT 229 11 110 7 92 5 
S91G 245 5 87 3 92 6 
R128W 241 10 108 12 92 1 
S250R 288 6 90 1 75 7 
K284R 247 9 98 6 92 7 
M320T 267 5 91 3 75 8 
G372E 241 5 105 3 95 1 
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Figure 12: Growth curves of the wild type and the mutant cbf5 strains at different 
temperatures in liquid rich medium. The graphs on the left are for the wild type, cbf5 
S91G, R128W and S250R at 18°C in the top, at 30°C in the middle and the 37°C in the 
bottom. Similarly, on the right are the graphs for the growth rate for the wild type, cbf5 
K284R, M320T and G372E.  
 
The data show that the wild type cells maintain a similar growth rate at 37°C to cells 
grown at 30°C. All mutant strains were compared to the wild type cells and as was 
observed at 30°C, all mutants grew at least as fast as the wild type cells and displayed 
temperature resilience. Some growth curves will need to be reproduced to assess whether 
some mutations enable a faster growth than wildtype (S250R, K284R). Lastly, we 
examined the growth rate at 18°C, and for most mutants, no detectable phenotype was 
observed (Figure 12 & Table 3). However, the mutants S250R and M320T displayed a 
slight decrease in doubling time suggesting a mild cold sensitivity for these strains. 
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For the growth analysis on a solid YEPD medium, serial of dilutions are made and plated 
on YEPD + agar medium. The plates are left to incubate at 30°C, 37°C and 18°C 
respectively for 48-72 h. The results indicate that all strains were able to grow in a similar 
manner as the wild type at 30°C. Moreover, the growth behavior did not change at 37°C 
and 18°C and and remained similar to the wild type (Figure 13).   
 
Figure 13: Growth analysis on solid rich medium at different temperatures. The 
different yeast strains are labelled on the right whereas the number of cells is 
described either above or below each plate. The temperature of the test is 
indicated in the middle.  
 
4.3 Quantification of Cbf5 protein levels 
Western blotting was used to examine ScCbf5 protein levels in whole-cell extracts of the 
mutant yeast strains and to compare these to the wild type Cbf5 protein levels. Yeast cells 
were grown to the mid-point of the exponential growth phase, and a 2 OD600 sample was 
collected. The samples were subjected to alkaline extraction, and total protein from each 
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yeast strain (wild-type and mutants) was then separated by SDS-PAGE (Figure 14). The 
proteins were transferred from the SDS gel to a nitrocellulose membrane for Western 
blotting (Figure 15).  
 
Figure 14: SDS-PAGE of yeast whole-cell extract from wild-type and mutant yeast 
strains. Whole cell extract was prepared using the alkaline extraction method. Cbf5 is 
approximately 55 kDa in size.  
 
 
Figure 15: Western blot of Cbf5 from wild-type and mutant yeast strains. For Western 
blotting, a primary antibody against a small peptide chain in the C-terminus of Cbf5 was 
generated. The membrane was stripped and incubated with PGK1 primary antibody to 
show PGK1 as a loading control. Relative intensity of Cbf5p bands is indicated beneath 
each band. As a control (left lane), ScCbf5 protein was loaded that was expressed in E. 
coli and purified using a hexahistidine tag; as this recombinant Cbf5 protein may not be 
phosphorylated in contrast to endogenous Cbf5 in yeast, it may migrate a bit slower on 
the gel. 
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Several bands were detected including one that corresponded in size to the molecular 
weight of Cbf5. The membrane was stripped and then incubated with primary antibody to 
detected phosphoglycerate kinase (PGK1) as a loading control. 
As shown in Figure 15, Cbf5 is visible in all samples. To quantify Cbf5 levels in each of 
the samples Image J software was used to determine band intensity and to normalize the 
Cbf5 level relative to the loading control PGK1. This analysis revealed that all Cbf5 
variants are expressed at levels comparable to wild-type Cbf5. It will be necessary to 
reproduce this experiment to determine standard deviations for the relative Cbf5 levels in 
the mutant strains. 
 
4.4 Examination of the cell cycle in yeast strains 
The following experiment was used to investigate any unusual delay of cell cycles phases 
in the mutant strains. Towards this aim, yeast cells were stained with propidium iodide 
after synchronization with nocodazole and subsequently analyzed by flow cytometry to 
detect the propidium iodide-stained DNA levels. To examine the distribution between G1 
and G2 phases, cells were collected at specific time points after removal of nocodazole. 
The first sample was collected from cell culture before the addition of nocodazole. Figure 
16 shows that the G1 and G2 phases are clearly represented as two independent peaks in 
propidium iodide fluorescence corresponding to 1n and 2n DNA content, respectively. 
The G2 peak is larger than the G1 peak. Next, nocodazole was added to the cultures 
which were allowed to incubate until 95% of the cells reached the G2/M phase. This was 
evident under the microscope where all cells exhibited the presence of buds, with 
daughter cells similar in size to the parent cells. At this particular point, cells were 
collected for the flow cytometry analysis. Figure 16 shows that all strains, including the 
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wildtype strain, appear to be stalled at the G2 phase while the G1 phase is represented 
only by a small peak. After a 3-hour incubation with nocodazole, the cells were pelleted 
and washed twice with distilled water and then re-incubated with fresh pre-warmed 
medium. By doing this, the cells were able to resume the cell cycle in a synchronized 
fashion. Samples after 15-20 min of releasing from the cell cycle are collected: at this 
time point, the G1 peak is getting larger again indicating that cell cycle is progressing and 
that the cells stalled in G2 previously have no divided and reached the G1 phase. After 2 
h of incubation, cells are also collected, and the data shows that the cell population, that is 
in G2 phase, is much greater than the cell population in G1 phase. This indicates that the 
cells, that had just divided at the previous time point (15-20 min) and were in G1 phase 
have no duplicated their genome reaching the G2 phase. After 4 h, the results show that 
the G1 peak has increased again slightly, and after 6 h, both a pronounced G1 peak and a 
clear G2 peak can be observed suggesting that cells are progressing through the cell cycle 
and that the population is becoming asynchronous again. This trend is consistent across 
all strains, and no apparent abnormality in the mutant strains compared to the wild-type is 
observed.   
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Figure 16 A: Cell cycle analysis by flow cytometry of wild-type and mutant yeast strains. 
The cell cycle was arrested in the G2 phase by nocodazole and synchronized progression 
through the cell cycle was monitored after removal of nocodazole. The x-axis shows the 
fluorescence of propidium iodide. The data set for the wild-type is shown in each panel in 
black for direct comparison (legend is continued on next page).  
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Figure 16 B: continued. Yeast cells were stained with propidium iodide for flow 
cytometry analysis. Panel A) shows histograms at different time points for the wild-type 
(in black), cbf5 S91G (green), cbf5 R128W (orange) and cbf5 S250R (purple) yeast 
strains. Panel B) shows flow cytometry histograms at different time points for the WT 
overlaid in black with cbf5 K284R (purple), cbf5 M320T (blue) and cbf5 G372E (green) 
yeast strains.   
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Chapter 5. Discussion 
 
Here, I constructed six yeast strains which each have a single mutation in the cbf5 gene 
and screened the strains for phenotypes. All strains grow similarly to the wild type at the 
optimal temperature (30°C) in rich medium; similar results were also observed at 18°C 
and 37°C. In rich solid medium, all mutants also exhibit similar growth behavior as the 
wild type. The next assay was to examine Cbf5p expression levels across strains via 
western blotting. This analysis reveals that Cbf5 expression levels are relatively similar 
among the mutant strains and the wild type strain. Finally, all strains were characterized 
for progression through the cell cycle following nocodazole treatment using flow 
cytometry; no difference between the wild type and the constructed strains was observed. 
The overall conclusion of this study is that single Dyskeratosis congenita mutations in 
cbf5 are highly tolerated in yeast even though the counterpart mutations in humans cause 
severe symptoms. In the following, I will speculate how these results can be explained in 
the context of current literature on H/ACA sRNPs. 
Firstly, the protein constituents of H/ACA sRNPs are bound to less than 100 different 
H/ACA RNAs in yeast (Lestrade and Weber 2006). The population of H/ACA RNAs in 
humans is significantly greater than in yeast (Dieci, Preti et al. 2009, Ketele, Kiss et al. 
2016). Furthermore, human H/ACA RNAs are the precursors for microRNAs and Piwi-
associated RNAs (Scott, Avolio et al. 2009). This difference could explain why there is 
no obvious phenotype in the constructed yeast strains. Moreover, H/ACA RNA 
expression levels in human are tissue-dependent and stress-dependent. Deregulation of 
H/ACA RNA levels can be used as a biological marker for diseases such as many types of 
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cancer. Therefore, a great range of symptoms can be expressed in humans whereas in a 
single cell such as yeast, a phenotypic effect manifests typically as slower growth.  
Secondly, studies conducted on human cell lines with dkc1 being mutated showed that 
overall translation fidelity of mRNA by ribosomes was relatively normal (Jack, Bellodi et 
al. 2011, Penzo, Rocchi et al. 2015). However, the ribosomes failed to translate certain 
type of mRNAs containing an IRES element. At least 30 IRES mRNAs were found in 
human tissues such as brain tissues, and some mRNAs that are involved in apoptosis 
contain an IRES structure as well (Hellen and Sarnow 2001, Penzo, Rocchi et al. 2015). 
In yeast, there are seven mRNAs containing an IRES element  which are could play a role 
in invasive growth (Gilbert, Zhou et al. 2007). But not much is known about other IRES-
containing mRNAs in yeast, and their importance for cellular growth. In addition, it has 
been shown that yeast cells with pseudouridine-free ribosomes are still viable, but display 
a severe slow-growth phenotype (Zebarjadian, King et al. 1999), whereas deregulation of 
one of the pseudouridine-guiding H/ACA RNAs is linked to cancer in humans (Taft, Pang 
et al. 2010, Esteller 2011). These findings could suggest that unlike yeast, the human 
biological system is more complex and highly sensitive to slight alterations.  
Therefore, to see phenotypic effects in yeast strains, we may have to combine several 
Dyskeratosis congenita mutations in each yeast strain. In future, we need to be strategic 
while choosing mutations to be implemented. Based on the H/ACA sRNP crystal 
structure, there are few possible types of mutations in Cbf5 that we can investigate. One 
obvious strategy is to target the PUA domain, where we could focus on interfering with 
guide RNA binding. We could make mutations that make the binding to the guide RNA 
either stronger or weaker. The PUA domain is highly positively charged and thereby 
binds to the H/ACA RNA. We could design the PUA domain in in a way that makes it 
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almost completely positively charged which could possibly further increases the affinity 
to guide RNA. However, the danger of this strategy is that the PUA domain could 
become destabilized by a too high density of positive charges on the protein surface. One 
consequence of mutations that tighten binding of the PUA domain in Cbf5p to the guide 
RNA could be to make the H/ACA sRNP complex very rigid and thus eliminate intrinsic 
flexibility in the complex that is needed for the interaction with the substrate RNA. 
Alternatively, we can weaken the interaction of the PUA domain with guide RNA by 
introducing negatively charged residues. We could then test the effect of amino acid 
substitutions in Cbf5 in vitro by measuring pseudouridylation of target uridines in a 
variety of substrate RNAs using a tritium release assay and by determining the affinity for 
guide RNA and substrate RNA by nitrocellulose filtration (Kamalampeta and Kothe 
2012). In addition, it has been speculated that H/ACA sRNPs could be functioning as 
RNA chaperones (Keffer-Wilkes, Veerareddygari et al. 2016).In this case, one feature 
that we can test is the rRNA profile to assess processing of rRNA from pre-rRNA by 
pulse-chase labeling of rRNA with radiolabeled [
3
H]-methionine in exponentially 
growing cells. Eventually, pre-rRNA variants will be processed into fully mature rRNA, 
but it could be much slower than in the wild type. We could also subject ribosomes to 
sucrose gradient centrifugation to examine the polysome profile and the 40S to 60S ratio 
(Liang, Liu et al. 2007). In addition, we could examine pseudouridine content compared 
to the wild type.  
Many transacting factors are involved in ribosome biogenesis, and in humans about 100 
H/ACA sRNPs are crucial factors in pre-RNA maturation. These H/ACA sRNPs are 
involved in pre-rRNA biogenesis at different time points. Therefore, we could test the 
hierarchy of different H/ACA sRNPs interacting with pre-rRNA. We could do that by 
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integrating a MS2-tagged guide RNA into the yeast genome. Next we could target this 
MS2-H/ACA RNA with a fusion protein of MS2 protein and a red fluorescent protein. 
We can next similarly insert another RNA tag such as RNA mango to the 5`end of the 
pre-rRNA (Dolgosheina, Jeng et al. 2014). We could then detect co-localization of the 
guide RNA and the pre-rRNA by dual fluorescence microscopy. Thereby, we could 
observe the lifetime of H/ACA sRNPs pairing and dissociation from pre-rRNA with the 
help of the fluorescent signal. This could also be particularly interesting regarding the 
snR30 H/ACA RNA in yeast as we could study when it base-pairs with pre-rRNA 
(Lemay, Hossain et al. 2011). snR30 is involved in pre-rRNA maturation, but the full 
mechanism is not fully understood. Understanding the interaction of this particular guide 
RNA could add significant information to the process of ribosome biogenesis. This 
fluorescence microscopy assay could also be used to assess the effects of cbf5 mutations 
on ribosome biogenesis in vivo. 
Once we get a yeast strain with one or more Dyskeratosis congenita mutations that has a 
phenotypic effect, we could test whether the overall pseudouridylation level will decrease 
or increase in the cell. Few studies have shown that during stress, the pseudouridylation 
level increases in noncoding RNA as well as mRNA (Li, Zhu et al. 2015). Another study 
has shown that when PUS1 is knocked out, its target uridine in U2 snRNA still gets 
pseudouridylated by an H/ACA sRNP (Deryusheva and Gall 2017). We could test this 
hypothesis by HPLC analysis of total RNA and then compare the level of pseudouridines 
formation in mutant strains relative to the wild type.  
Finally, I propose making more Dyskeratosis congenita mutations in the unstructured C-
terminal tail of Cbf5 including a complete deletion of this part of Cbf5. This location has 
not been investigated in eukaryotes, and this approach could provide information about 
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the earlier stages of H/ACA sRNP biogenesis, and also about the final location of H/ACA 
snoRNPs in the nucleolus as the tail could contribute to the gel-like structure of the 
nucleolus (Thiry and Lafontaine 2005). It is not known if the tail region in Cbf5p gets 
phosphorylated right after translation or if it gets first covered by Shq1. Deletion of the C 
terminus could also allow us to discover new protein partners that interact with the 
complex via the unstructured tail. Interestingly, upon Shq1p binding, the tail region in 
Cbf5 becomes highly structured (Li, Duan, Li, Ma et al. 2011). Cbf5p is heavily modified 
post-translationally in the N terminus, the PUA domain and in the C terminus. Notably, 
Dkc1p in humans and also Dkc1p in rats are modified in the same regions as yeast Cbf5p 
(Robles, Humphrey et al. 2016) (Swaney, Beltrao et al. 2013). 
The vast majority of these post-translation modifications are phosphorylations. This could 
imply that modification of Cbf5 regulates its activity in the cell which raises the question 
regarding the functional difference of modified Cbf5 and unmodified Cbf5. Can we 
classify unmodified Cbf5p as inactive while the modified one is active or vice versa? 
Could it be that the phosphorylated tail triggers a signal in the cell? Or could it activate 
undiscovered or uncharacterized functions of Cbf5 in the cell? These and more questions 
can be answered by making yeast strains where the phosphorylation sites of Cbf5 are 
mutated to aspartate to mimic phosphorylation, or alanine, or where the tail is deleted 
completely. 
In conclusion, Dyskeratosis congenita seems to be caused by disrupted pathways in the 
cell that might be specific to humans or mammals, and impaired ribosome biogenesis 
could be only one of several affected pathways since the H/ACA sRNPs complex is 
involved in pre-rRNA processing as well as incorporation of pseudouridines in rRNAs. 
Thus, introducing more or other Dyskeratosis congenita mutations in a simple eukaryote 
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such as yeast could in the future reveal affected step(s) with respect to ribosome 
biogenesis. 
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Appendices 
 
 
 
Figure A1: The full-size membranes of the western blot of Cbf5 from wild-type 
and mutant yeast strains. Panel A) shows the whole membrane with the PGK1 
loading control. In panel B), the membrane is shown that was incubated with the 
primary anti-Cbf5 antibody, and the intensity was slightly adjusted using Irfan 
View software. On the right of panel B) is the same membrane without any 
intensity adjustment.  
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Figure A2: Flow cytometry data including gating information for the mutations in the 
catalytic domain of Cbf5p as well as the wild-type. The gating for the representative wild-
type is shown in the left plots and the resulting histograms for wild-type and mutants are 
depicted on the right plots). The same gating was consistently used throughout the 
analysis for all data (time points and strains).  
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Figure A3: Ungated Flow cytometry data. On this page, histograms are shown for the 
mutants that are located in the catalytic domain (each overlaid onto wild-type in black).  
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Figure A3: continued (Ungated Flow cytometry data). This second page shows ungated 
flow cytometry data for the mutants that are located in the PUA domain overlaid onto 
wild-type in black. 
